Laura F Newell1, Shernan G Holtan2, Jane E Yates3, Leonardo Pereira4, Jeffrey W Tyner1,5, Irina Burd6, Grover C Bagby1,3. 1. Hematology and Medical Oncology, Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA. 2. Division of Hematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN, USA. 3. Northwest Veterans Affairs Cancer Research Center, Portland, OR, USA. 4. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR, USA. 5. Department of Cell, Development, and Cancer Biology, Oregon Health & Science University, Portland, OR, USA. 6. Department of Gynecology and Obstetrics, Integrated Research Center for Fetal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abstract
PROBLEM: Levels of placental growth factor (PlGF) peak during third trimester of pregnancy, a time when women are at increased risk of virus-induced morbidity. We hypothesized PlGF might contribute to an exaggerated inflammatory response to Toll-like receptor (TLR) activation. METHOD OF STUDY: Primary human adult and cord blood CD14+ cells were cultured in the presence of TLR ligands and/or PlGF. RESULTS: PlGF significantly enhanced the magnitude and duration of TNF messenger RNA and protein production by TLR-7/8-activated monocytes, and increased subsequent production of TNF-independent inflammatory cytokines. This PlGF/TLR effect involved multiple inflammatory cytokines/chemokines and was seen with the majority of TLR agonists. PlGF enhanced phosphorylation of IkappaB kinase (IKK) in monocytes stimulated with the TLR-7/8 agonist R848, and IKK inhibition completely suppressed the PlGF effect. CONCLUSION: PlGF enhances TLR-signaling upstream of IKK and contributes to an exaggerated pathologic pro-inflammatory state in response to activation of maternal and fetal mononuclear phagocytes by specific TLR agonists.
PROBLEM: Levels of placental growth factor (PlGF) peak during third trimester of pregnancy, a time when women are at increased risk of virus-induced morbidity. We hypothesized PlGF might contribute to an exaggerated inflammatory response to Toll-like receptor (TLR) activation. METHOD OF STUDY: Primary human adult and cord blood CD14+ cells were cultured in the presence of TLR ligands and/or PlGF. RESULTS:PlGF significantly enhanced the magnitude and duration of TNF messenger RNA and protein production by TLR-7/8-activated monocytes, and increased subsequent production of TNF-independent inflammatory cytokines. This PlGF/TLR effect involved multiple inflammatory cytokines/chemokines and was seen with the majority of TLR agonists. PlGF enhanced phosphorylation of IkappaB kinase (IKK) in monocytes stimulated with the TLR-7/8 agonist R848, and IKK inhibition completely suppressed the PlGF effect. CONCLUSION:PlGF enhances TLR-signaling upstream of IKK and contributes to an exaggerated pathologic pro-inflammatory state in response to activation of maternal and fetal mononuclear phagocytes by specific TLR agonists.
Authors: Howard A Kader; Velizar T Tchernev; Ebenezer Satyaraj; Serguei Lejnine; Gregory Kotler; Stephen F Kingsmore; Dhavalkumar D Patel Journal: Am J Gastroenterol Date: 2005-02 Impact factor: 10.864
Authors: David L Boone; Emre E Turer; Eric G Lee; Regina-Celeste Ahmad; Matthew T Wheeler; Colleen Tsui; Paula Hurley; Marcia Chien; Sophia Chai; Osamu Hitotsumatsu; Elizabeth McNally; Cecile Pickart; Averil Ma Journal: Nat Immunol Date: 2004-08-29 Impact factor: 25.606
Authors: Denise J Jamieson; Margaret A Honein; Sonja A Rasmussen; Jennifer L Williams; David L Swerdlow; Matthew S Biggerstaff; Stephen Lindstrom; Janice K Louie; Cara M Christ; Susan R Bohm; Vincent P Fonseca; Kathleen A Ritger; Daniel J Kuhles; Paula Eggers; Hollianne Bruce; Heidi A Davidson; Emily Lutterloh; Meghan L Harris; Colleen Burke; Noelle Cocoros; Lyn Finelli; Kitty F MacFarlane; Bo Shu; Sonja J Olsen Journal: Lancet Date: 2009-07-28 Impact factor: 79.321
Authors: Scott M Vanderwerf; Johanna Svahn; Susan Olson; R Keaney Rathbun; Christina Harrington; Jane Yates; Winifred Keeble; David C Anderson; Praveen Anur; Noemi F Pereira; Daniela V Pilonetto; Ricardo Pasquini; Grover C Bagby Journal: Blood Date: 2009-10-22 Impact factor: 22.113
Authors: Sarah J Germain; Gavin P Sacks; Suren R Sooranna; Suren R Soorana; Ian L Sargent; Christopher W Redman Journal: J Immunol Date: 2007-05-01 Impact factor: 5.422
Authors: Julia E Brittain; Ben Hulkower; Susan K Jones; Dell Strayhorn; Laura De Castro; Marilyn J Telen; Eugene P Orringer; Alan Hinderliter; Kenneth I Ataga Journal: Blood Date: 2009-12-29 Impact factor: 22.113
Authors: Asitha T Silva; Farzana Rouf; Oluwayemisi A Semola; Mark E Payton; Pamela C Lovern Journal: Am J Physiol Heart Circ Physiol Date: 2019-08-09 Impact factor: 4.733